Urine-Derived CD105-Positive Exosome Promotes Macrophage M1 Polarization Through the TGF-β1/Smad3 Signaling Axis To Exacerbate Lupus Nephritis Authors: Yanmin Pang, Xiuhong Pan, Linlin He, Yao Zuo, Xiaochao Wang, Yanwu You Published: 2025 ABSTRACT This study investigated the regulatory role of exosomal CD105 in macrophage polarization and its mechanisms in lupus nephritis (LN). Analysis of samples from 20 LN patients revealed significant CD105 overexpression in kidney tissues and urinary exosomes. Exosomes were isolated from the urine specimens and tested for CD105 expression levels. Exosomes overexpressing or knocking down CD105 were co-cultured with macrophages to detect the levels of M1/M2 markers (CD86, IL-6, ARG-1, and IL-10) and changes in the TGF-β1/Smad3 pathway. Rescue experiments were performed using the TGF-β1 agonist (80116-RNAH) and inhibitor (SB431542). For in vivo experiments, exosomes overexpressing or knocking down CD105 were injected into a systemic lupus erythematosus model mice (MRL/lpr) to observe changes in renal inflammation and M1 macrophage infiltration. CD105 was significantly overexpressed in LN kidney tissues and urinary exosomes. CD105 overexpression in exosomes led to a decrease in p-Smad3 levels, up-regulation of M1 markers (CD86/IL-6), and down-regulation of M2 markers (ARG-1/IL-10); on the other hand, CD105 knockdown had the opposite effect in exocytosis. 80,116-RNAH reversed the effects of CD105-induced M1 polarization. In vivo experiments confirmed that CD105 overexpression in exosomes exacerbated renal inflammation and M1 macrophage infiltration, while CD105 knockdown in exosomes attenuated renal injury. Exosomal CD105 critically drives LN progression by inducing macrophage M1 polarization through inhibition of the TGF-β1/Smad3 signaling axis. Our findings provides a new direction for the study of LN pathogenesis and the development of therapeutic targets.Supplementary InformationThe online version contains supplementary material available at 10.1007/s10753-025-02377-3. Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-system and multi-organ involvement [1]. Lupus nephritis (LN) is one of the most common and severe complications in patients with SLE, and is significantly associated with mortality [2]. The pathological features of LN include immune complex deposition, macrophage infiltration, and glomerulosclerosis [3]. Macrophages have a dual role in LN progression: classically activated M1 macrophages exacerbate inflammation through proinflammatory cytokines, while alternatively activated M2 macrophages promote tissue repair [4]. Recent studies have shown that macrophage polarization imbalance is associated with adverse renal outcomes in patients with LN [5, 6]. Given the dual role of macrophages in LN and the importance of intercellular communication in autoimmune diseases, the regulatory role of exosomes in macrophage polarization has attracted increasing attention. Recent studies have revealed the potential of exosomes as prognostic biomarkers and therapeutic targets in immunotherapy [7, 8]. Among them, urinary exosomes are enriched with renal-derived proteins and miRNAs, which can reflect renal pathology and modulate immune cell behavior [9]. Studies have shown that plasma exosomes in patients with SLE exacerbate LN by modulating macrophage M1 polarization [10]. CD105 (endoglin, a TGF-β1 co-receptor) is a vascular endothelial glycoprotein, an important endothelial cell co-receptor of the transforming growth factor β (TGF-β) superfamily, which plays an important role in angiogenesis regulation and fibrosis. Additionally, it also has a modulatory role in inflammatory and immune responses [11–13]. A previous study showed that CD105 expression is elevated in the peripheral blood of patients with SLE and correlates with disease activity [8]. CD105 expression is also elevated in various inflammatory conditions, including SLE, and is associated with increased levels of pro-inflammatory cytokines [14]. This suggests that CD105 may promote inflammatory responses by enhancing M1 macrophage polarization [15]. The TGF-β1/Smad3 pathway plays an important role in immune regulation and tissue fibrosis, and its aberrant regulation is closely related to a variety of autoimmune diseases [16]. TGF-β1 regulates gene expression and affects cell proliferation, differentiation, and apoptosis by binding to its receptor and activating the Smad2/3 complex [17]. Moreover, CD105, primarily expressed in endothelial cells and fibroblasts, can function as a co-receptor of TGF signaling. In several human organs, endoglin tends to be upregulated when chronic damage and fibrosis occurs [18]. Additionally, it has been suggested that the aberrant activation of the TGF-β1/Smad3 pathway is closely related to renal inflammation and fibrosis in cases of LN [19]. Given that CD105 can modulate the TGF-β1/Smad3 pathway and that this pathway is implicated in both immune regulation and fibrosis, it is plausible that CD105 overexpression in exosomes could drive M1 macrophage polarization by regulating the TGF-β1/Smad3 signaling axis. However, the specific regulatory role of exosomal CD105 on the TGF-β1/Smad3 pathway and its effect on LN remains unclear.Therefore, in the present study, we aimed to explore the regulatory role of exosomal CD105 in macrophage polarization during LN development and understand the underlying molecular mechanisms. Materials and Methods Patients and Methods In this study, we included 20 patients diagnosed with LN at the Department of Nephrology of Affiliated Hospital of Youjiang Medical University for Nationalities from June 2022 to June 2024. The criteria for the diagnosis of LN were in accordance with the diagnostic and categorization criteria of the American College of Rheumatology (ACR) and/or the Systemic Lupus International Collaborative Clinic (2012). The class of LN was determined based on renal biopsy findings and classified according to the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification system. Specifically, 3 were diagnosed with Class III LN, 6 with Class IV LN, 3 with Class III + V LN, and 8 with Class IV + V LN. All patients were diagnosed during the active phase of the disease and were treatment-naive. Ten healthy individuals, matched for sex and age, were also recruited from the physical examination department as controls. Prior to enrollment, all healthy controls underwent screening tests to exclude potential undiagnosed kidney disease. Specifically, urine analysis was performed to check for proteinuria and hematuria. Only individuals testing negative for both proteinuria and hematuria were included in the healthy control group. Paracancerous tissue sections of five patients with renal cancer were also obtained from the specimen bank. Clinical samples were collected and processed with the approval of the Ethics Review Committee of the Affiliated Hospital of Youjiang Medical University for Nationalities (Clinical trial number: 2022092005). Written informed consent was obtained from both healthy individuals and patients with LN. The clinical and demographic characteristics of these patient samples are presented in Supplementary Tables 1 and 2. Exosome Isolation and Characterization From each participant, 100 mL of morning urine was collected and centrifuged (300 g × 10 min) within 2 h; the supernatant was collected, and centrifuged at 2000 g for 20 min. The resulting supernatant was vortexed-shaken for 1 min and then centrifuged at 3,000 g for 10 min. Thereafter, the supernatant was subjected to 120 min of centrifugation at 120,000×g. The precipitants obtained by centrifugation were exosomes. To quantify and measure the size of the exosomes, they were analyzed using the nanoparticle tracking analysis (NTA) technique. To investigate exosome morphology, images of exosomes were obtained by transmission electron microscopy (TEM). Exosomes were loaded onto a formvar-coated grid after being treated with 2% paraformaldehyde. Thereafter, 2% uranyl acetate was used to negatively stain the exosomes. Double-steamed water was used to wash the stained exosomes. Images were taken once the material had dried at room temperature. Western blotting (WB) was used to analyze the expression levels of CD9 (ab236630, 1:1000; Abcam), CD63 (ab134045, 1:1000; Abcam), TSG101 (ab125011, 1:1000; Abcam), and calnexin (10427-2-AP, 1:5000; ProteIntech). Exosome Uptake Assay PKH67 (a green fluorescent dye, Sigma-Aldrich, USA) was used to label the exosomes to track their uptake by macrophages. Subsequently, we examined the samples using confocal microscopy at 24 h following the PKH67 treatment. Pathological Assessment of the Kidneys Kidney tissues were first fixed in a solution containing 4% paraformaldehyde, then embedded in paraffin, and cut into 4 μm thick sections. These sections were stained using hematoxylin-eosin (H&E) staining. Additionally, selected sections were subjected to immunohistochemical (IHC) staining to further evaluate specific protein expressions and cellular markers. Quantification of histologic changes in the kidneys was performed by methods described in a previous study [20]. Specifically, the pathological changes in each glomerulus were assessed in a semi-quantitative manner by examining 20 glomerular cross-sections from each kidney sample. The assessment was based on histopathological indices including glomerulocytosis, mesangial matrix expansion, lymphocytes infiltration, focal necrosis, hyalinosis and crescent formation. Immunofluorescence (IF) For IF experiments, 1 × 104 macrophages were inoculated into confocal dishes and cultured for 24 h. After 24 h, they were treated with a 4% paraformaldehyde fixative for 30 min. Subsequently, they were permeabilized with 0.1% TritonX-100-PBS for 20 min and closed with 10% bovine serum albumin for 30 min. Next, primary antibodies for CD86 (1:200), pSmad3 (1:200), IL-6 (1:200), and IL-10 (1:200) were added and incubated at 4°C overnight. Afterwards, the nuclei were incubated with a fluorescent secondary antibody for 1 h in the dark, and 1–2 drops of 4’,6-diamidino-2-phenylindole (DAPI) were added for nuclear staining for 10 min. This was then followed by the addition of an anti-fluorescence quencher. Mouse kidney tissue sections were first deparaffinized with xylene, then dehydrated in a graded ethanol series, and boiled in ethylenediaminetetraacetic acid buffer (pH 8.0) for 20 min to repair antigens. For closure, 10% bovine serum albumin was added for 1 h. Next, a primary antibody was added, and the tissue sections continued to be incubated overnight at 4 °C. After 1 h of incubation, a fluorescent secondary antibody (1:200) was added, followed by 1–2 drops of DAPI for nuclear staining for 10 min. Finally, anti-fluorescence quencher was added. Images were taken using a laser scanning confocal microscope (FV3000). RNA Extraction, cDNA Synthesis, and qRT-PCR Total RNA was extracted using the Total RNA Extraction Kit (AXYGEN, USA). mRNA was reverse transcribed to cDNA using the First Strand cDNA Synthesis Kit (Mona Bio, China) according to the manufacturer’s procedure. qRT-PCR was performed using SYBR Green qRT-PCR Master Mix (Mona Bio, China) according to the instructions. qRT-PCR was performed using three replicate samples. The relative expression of the genes was calculated by the 2-ΔΔCt formula. Cell Line Cultures Human embryonic kidney cells (HEK-293T) and RAW264.7 macrophages were obtained from Shanghai Institute of Cell Biology, Chinese Academy of Sciences, and each cell line was accompanied by a STR identification report to ensure their authenticity. The cells used in the experiments were less than 25 generations and freshly frozen. HEK-293T cells and RAW264.7 macrophages were cultured in a complete medium containing 10% fetal bovine serum (FBS, Bio-channel) and 1% penicillin-streptomycin at 37℃ and 5% CO2. Cells in the logarithmic growth phase were used for the in vitro experiments. Lentiviral Transfection of HEK-293T Cells To ensure the knockdown and overexpression of CD105, knockdown and overexpression lentiviruses were purchased from Shanghai GK GeneChem Technology Co. The two vector plasmids that make up the lentiviral vector system are GV492/GV493.The three knockdown lentiviruses and knockdown negative control viruses were named as CD105-RNAi#1, CD105-RNAi#2, CD105-RNAi#3, and CON313 according to the designation given to them by Shanghai Gikai Gene Chemistry Co. Overexpression of CD105-OE and the control CON335 was performed in 6-well plates in which the cells were transfected with 5 × 107 TU/mL (MOI = 50) of virus stock solution. HEK-293T was inoculated into the 6-well plates at 1 × 104 cells/well, and the viral stock solution was transfected into HEK-293T cells at 5 × 107 TU/mL (MOI = 50). They were then cultured in Dulbecco’s Modified Eagle Medium (DMEM) complete medium containing 10% FBS, and placed in an incubator at 37℃ with 5% carbon dioxide for 8–12 h; thereafter, the solution was changed. After 72 h of transfection, 5–10 µg/mL puromycin was added, and screened for 48 h, and a stable lentiviral transfection strain was obtained for subsequent experiments. The lentiviral stable transfections were obtained for subsequent experiments. The lentivirus with the most obvious knockdown effect was selected to construct the stable transplants. The same method was used to construct the stable transplants overexpressing CD105. After the stable strain was screened and replaced with exosome-free medium, the culture was continued for 48 h. Thereafter, the cell supernatant was collected, and ultracentrifugation was used to obtain exosomes from the cell supernatant in order to infect the RAW264.7 macrophages. RAW264.7 Macrophage Modelling and Grouping RAW264.7 macrophage cultures were cultured in DMEM containing 10% FBS, and exosomes were harvested using ultracentrifugation in conditioned medium from overexpressing/knockdown CD105 and control cells, respectively. Moreover, TGF-β1 agonist (80116-RNAH) and inhibitor (SB431542) were used for cellular intervention. The RAW264.7 macrophages were assigned to eight groups: (1) oeNC-exo group (overexpression of negative control exosomes, [20 µg/mL]); (2) oeCD105-exo (overexpression of CD105 exosomes, [20 µg/mL]); (3) oeCD105-exo + recombinant TGF-β1 group (overexpression of CD105 exosomes [20 µg/mL] and TGF-β 1 [10 ng/mL]); (4) oeCD105-exo + 1% BSA (overexpression of CD105 exosome intervention [20 µg/mL] and TGF-β1 control solvent 1% BSA); (5) shNC-exo group (knockdown of negative control exosome, [20 µg/mL]); (6) shCD105-exo (knockdown of CD105 exosomes [20 µg/mL]); (7) shNC-exo + SB431542 group (knockdown of CD105 exosomes [20 µg/mL] and TGF-β1 inhibitor SB431542[80 μm]); and (8) shCD105-exo + 0.1% DMSO (knockdown of CD105 exosomes [20 µg/mL] and SB431542 control solvent 0.1% DMSO). Cells were cultured at 37 °C and 5% CO2 in a cell incubator for 48 h. RNA and protein were collected after 48 h for subsequent experiments. WB Kidney tissue and macrophages from mice were lysed in the RIPA lysate and then centrifuged at 4 °C and 12,000 rpm for 5 min to collect the supernatant. Protein concentration was determined using the bisulfonylurea method. After sodium dodecyl sulfate polyacrylamide gel electrophoresis, denatured proteins were transferred to a polyvinylidene difluoride membrane. The membranes were blocked in TBST (containing 5% skimmed milk) for 1 h and incubated with primary antibody at 4 °C overnight. The membranes were washed three times with TBST (45 min total). The washed membrane was incubated with secondary antibody for 1 h at room temperature. The membranes were developed by enhanced chemiluminescence reagents and analyzed using ImageJ 1.8.0 software (National Institutes of Health, Bethesda, MD) to calculate the expression of each protein. Animal Experiments MRL/lpr lupus mice were purchased from Hangzhou Ziyuan Laboratory Animal Science and Technology Co Ltd (SCXK [Zhe] 2024-0004). The mice were housed in the animal room of the Laboratory Animal Center of Youjiang Medical College for Nationalities in a specific pathogen-free environment with a light cycle of 12 h/12 h. There was an ambient temperature of 22–24 °C, and a relative humidity of 60–70%. Animal experiments were approved by the local ethics committee (Approval No.2024051001). All experimental manipulations were performed under anesthesia to minimize pain in the animals. Stable transfection of control vector and HEK-293T cell lines of shCD105 and oeCD105 were used for animal experiments and exosome isolation. First, to investigate the effect of exosome CD105 on SLE, all mice were divided into five groups (n = 5), including a PBS group (PBS), knockdown control exosome group (shNC-exo), CD105 knockdown exosome group (shCD105-exo), overexpression control exosome group (oeNC-exo), and a CD105 overexpression exosome group (oeCD105-exo). Thereafter, 100 µl of PBS and 60 µg/100 µl of shNC-exo, shCD105-exo, oeNC-exo, and oeCD105-exo, respectively, were injected intravenously into the tails of the mice in the PBS, shNC-exo, shCD105-exo, oeNC-exo, and oeCD105-exo groups, respectively, twice a week. All mice were sacrificed after 4 weeks, and the kidney tissues were dissected, collected, and weighed for H&E staining and WB, which were performed to detect the protein expression levels of the M1/M2 macrophage markers CD86, IL-6, IL-10, and ARG-1, and the pathway-associated proteins TGF-β1, Smad3, and pSmad3. Renal Histopathological Examination Standard staining techniques were employed on paraffin-embedded renal sections to evaluate distinct pathological features. General cellular architecture was assessed by Hematoxylin and Eosin (H&E) staining. The integrity of glomerular basement membranes and the presence of glycogen were examined using Periodic Acid-Schiff (PAS) staining. Finally, the degree of interstitial fibrosis was quantified following Masson’s Trichrome staining. Renal Function Test Kidney function was assessed by measuring serum creatinine (Scr) levels. This was done using a serum creatinine test kit (C011-2-1, Nanjing Jiancheng Bioengineering Institute, China) and instructions provided in the kit manual. Statistical Analysis Data were analyzed using SPSS 23.0 (IBM, Armonk, NY, USA) and GraphPad Prism 8.0 (GraphPad Software, San Diego, CA, USA). Continuous variables are presented as mean ± SD for normally distributed data and as median (IQR) for non-normally distributed data. Normality was assessed using the Shapiro-Wilk test, and homogeneity of variances was evaluated using Levene’s test. Comparisons between two groups were performed using t-tests, while one-way ANOVA with LSD or Tamhane T2 post hoc tests was used for multiple group comparisons, depending on variance homogeneity. P-value < 0.05 indicated statistical significance. Each experiment was repeated at least three times. Results Identification and Validation of Exosome CD105 in SLE Exosomes were isolated from the urine of healthy individuals and SLE patients. TEM showed that the exosomes exhibited a circular or round-like lipid bilayer membrane structure (Fig. 1A). NTA showed that normal urinary exosomes had a particle size of 153.8 nm and a concentration of 1.7 × 1012 particles/mL. SLE exosomes had a particle size of 172.2 nm and a concentration of 2.4 × 1012 particles/mL (Fig. 1B), consistent with previously reported exosome characteristics [21]. WB confirmed higher expression levels of exosome markers CD9 and CD63 and TSG101, and no expression of calnexin, in the urinary exosomes of healthy individuals and those with SLE, compared with the control cell lysate group (CL) (Fig. 1C). Previous quantitative proteomic analysis of whole-protein TMT markers in urinary exosomes from healthy controls and SLE patients revealed that CD105 was the first differentially expressed protein and was associated with inflammatory pathways. To further characterize the differential presence of CD105 in urinary exosomes, WB results showed that CD105 expression was significantly increased in urinary exosomes in the SLE group (P < 0.01)(Fig. 1D, E). Fig. 1Identification of urinary exosome characterization and validation of exosome CD105 in SLE. A TEM images of exosomes. B Normal individuals and patients with SLE with exosomes in the urine obtained by NTA. C Western Blot analysis of exosome markers CD9, CD63, and TSG101, with calnexin as a negative control. D&E Western Blot analysis of CD105 protein expression differences in urinary exosomes from healthy individuals and SLE patients. **** P < 0.0001 Identification of urinary exosome characterization and validation of exosome CD105 in SLE. A TEM images of exosomes. B Normal individuals and patients with SLE with exosomes in the urine obtained by NTA. C Western Blot analysis of exosome markers CD9, CD63, and TSG101, with calnexin as a negative control. D&E Western Blot analysis of CD105 protein expression differences in urinary exosomes from healthy individuals and SLE patients. **** P < 0.0001 Construction and Validation of Exosome CD105 To obtain CD105 knockdown and overexpression exosomes, HEK-293T cells were infected using a lentiviral transfection technique, and the transfection efficiency was detected by fluorescence (Fig. 2A). WB screened HEK-293T cell lines with low/high CD105 expression to establish knockdown/overexpression of CD105 stably-transformed cell lines. The WB results showed that the CD105 protein expression level of CD105-RNAi#1 was significantly reduced in the knockdown group compared with the control group (CON313 group), and the knockdown effect was the most significant (P < 0.05) (Fig. 2B, C). Compared with the control group (CON335 group), the CD105 expression of CD105-OE in the over-expression group was significantly higher, and the difference was statistically significant (P < 0.001) (Fig. 2B, D). Fig. 2CD105 knockdown/overexpression stable transfection strain establishment. A Efficiency of knockdown/overexpression of CD105 lentivirus transfection of HEK-293T cells. Scale bar = 50 μm. B-D Western Blot to detect the relative expression level of CD105 protein after lentiviral transfection of HEK-293T cells. *P < 0.05, ***P < 0.001 CD105 knockdown/overexpression stable transfection strain establishment. A Efficiency of knockdown/overexpression of CD105 lentivirus transfection of HEK-293T cells. Scale bar = 50 μm. B-D Western Blot to detect the relative expression level of CD105 protein after lentiviral transfection of HEK-293T cells. *P < 0.05, ***P < 0.001 Exosomal CD105 Promotes RAW264.7 Macrophage Polarization To M1 We first resuscitated the HEK-293T cell line with high expression levels of CD105 and negative control cell line and collected cell supernatants to obtain exosomes. To determine whether RAW264.7 macrophages could internalize exosomes, the exosomes were stained with PKH67 and the uptake of exosomes by RAW264.7 macrophages was assessed by using fluorescence detection. The results showed that a large number of exosomes entered the macrophages 24 h after exosome intervention (Fig. 3A). The use of PKH67 labelling allowed direct visualization of exosome uptake by macrophages, laying the foundation for further investigation of the physiological function of exosomes in macrophages. We then extracted RNA from the overexpressing control exosomes (oeNC-exo) and the CD105-overexpressing exosome group (oeCD105-exo) by intervening macrophages at 20 µg/mL for 24 h. The qRT-PCR results showed that the M1 macrophage markers CD86 and IL-6 were expressed significantly higher in the oeCD105-exo group than in the control group. Meanwhile, the M2 macrophage markers CD206 and IL10 were expressed significantly lower than that in the control group (P < 0.01) (Fig. 3B). These results suggest that exosomes from HEK-293T cells overexpressing CD105 can promote macrophage polarization to M1. Fig. 3Exosomal CD105 promotes macrophage polarization toward M1. A IF staining of exosomes and nuclei with PKH67 and DAPI, respectively, and microscopic observation of uptake after 24 h of exosome treatment are shown. Scale bar = 100 μm. B M1-polarized phenotype (CD86, IL-6) and M2-polarized phenotype (CD206, IL-10) were detected by qRT-PCR. C-D CD105, TGF-β1 and pSmad3 are detected by qRT-PCR. p-values are determined by t-tests of B-H. * P < 0.05, **P < 0.01, *** P < 0.001,**** P < 0.0001. oeNC-exo, cellular exosomes from overexpression controls. oeCD105-exo, cellular exosomes overexpressing CD105 Exosomal CD105 promotes macrophage polarization toward M1. A IF staining of exosomes and nuclei with PKH67 and DAPI, respectively, and microscopic observation of uptake after 24 h of exosome treatment are shown. Scale bar = 100 μm. B M1-polarized phenotype (CD86, IL-6) and M2-polarized phenotype (CD206, IL-10) were detected by qRT-PCR. C-D CD105, TGF-β1 and pSmad3 are detected by qRT-PCR. p-values are determined by t-tests of B-H. * P < 0.05, **P < 0.01, *** P < 0.001,**** P < 0.0001. oeNC-exo, cellular exosomes from overexpression controls. oeCD105-exo, cellular exosomes overexpressing CD105 We further investigated the specific mechanism by which CD105 exosomes induced macrophage M1 polarization. The TGF-β1/Smad3 pathway is a core pathway for macrophage M1 polarization. Using the qRT-PCR assay, we found that the expression level of CD105 was increased in macrophages treated with exosomes overexpressing CD105 (Fig. 3C), and the expression levels of TGF-β1 and pSmad3 were decreased compared with those of the control group (Fig. 3D). These results suggest that CD105 is a potential effector in exosome-mediated disease progression in SLE, while the TGF-β1/Smad3 pathway plays a major role in exosome-mediated M1 polarization. CD105 Expression and Macrophage Polarization in Renal Tissues of SLE The above findings imply a potential correlation between exosome-induced macrophage M1 polarization and the TGF-β1/Smad3 pathway. To further investigate macrophage infiltration and polarization in the kidney, we examined CD105 expression and M1-type macrophage infiltration by immunohistochemistry in renal tissues of patients with LN and used peritumoral renal tissue (PRT) as a control. The results showed that CD105 and CD86 levels were elevated, and pSmad3 was decreased in the LN kidney tissues in comparison to the renal paracarcinoma tissues (Fig. 4A). IF indicated prominent immune complex deposition in LN kidneys (Fig. 4D). Subsequently, we analyzed the localization of pSmad3 and the macrophage M1 polarization marker CD86 by IF. We found that pSmad3 and CD86 co-localized in LN kidney tissues (Fig. 4B, C), suggesting that TGF-β1/Smad3 were involved in macrophage M1 polarization in lupus kidney. The above results suggest that CD105-induced M1-type macrophage infiltration plays a key role in the progression of LN, and the TGF-β1/Smad3 pathway may also play an important role. Fig. 4High expression of CD86 and co-localization with pSmad3 in LN kidney tissues A Tissue immunochemistry is performed to detect CD105, CD86, and pSmad3 expression in LN kidney tissues and peritumoral renal tissues (PRT). Scale bar = 50 μm. B IF staining with anti-pSmad3 and anti-CD86 in LN tissues. Scale bar = 50 μm. C Fluorescence co-localization analysis of pSmad3 and CD86 in LN tissues. PRT: Peritumoral renal tissue. D Fluorescence microscopy image of immune complex and complement deposition. Scale bar = 50 μm High expression of CD86 and co-localization with pSmad3 in LN kidney tissues A Tissue immunochemistry is performed to detect CD105, CD86, and pSmad3 expression in LN kidney tissues and peritumoral renal tissues (PRT). Scale bar = 50 μm. B IF staining with anti-pSmad3 and anti-CD86 in LN tissues. Scale bar = 50 μm. C Fluorescence co-localization analysis of pSmad3 and CD86 in LN tissues. PRT: Peritumoral renal tissue. D Fluorescence microscopy image of immune complex and complement deposition. Scale bar = 50 μm Exosomal CD105 Promotes M1 Macrophage Polarization by Targeting the TGF-β1/Smad3 Signaling Pathway We further confirmed the interrelationship between CD105 and TGF-β1/smad3 by salvage experiments. We first treated RAW264.7 macrophages with exosomes overexpressing CD105, and then added TGF-β1 agonist and agonist-control solvents (1% BSA) to the treatment, respectively. The intracellular localization and expression of CD105 and pSmad3 proteins were observed by IF. The results showed that in macrophages, CD105 protein was mainly localized in the cell membrane and cytoplasm. The fluorescent signal was weak in the control group and significantly enhanced after oeCD105-exo intervention. Meanwhile, we observed that the pSmad3 protein was mainly expressed in the cytoplasm in the control group. Furthermore, the pSmad3 fluorescent signal was significantly enhanced and shifted to the nucleus after the treatment with TGF-β1 agonist (80116-RNAH), indicating that TGF-β1 could successfully activate the TGF-β1/Smad3 signaling pathway. In contrast, the fluorescence signal of pSmad3 was significantly weakened in the oeCD105-exo treatment group. In the IF images, the green fluorescent signal of pSmad3 co-localized with the red fluorescent signal of CD105 (Fig. 5A). WB results showed that treatment of exosomes overexpressing CD105 resulted in a significant increase in the M1-type polarizing factor CD86/IL-6 and a significant decrease in the M2-type polarizing factor IL-10/ ARG-1. After simultaneous intervention of CD105 overexpressing exosomes with TGF-β1 agonist, the expression level of CD86 /IL-6 was decreased and that of IL-10 /ARG-1 was increased. TGF-β1 agonist treatment reversed exosome-induced inhibition of macrophage M1 polarization and TGF-β1 pathway (Fig. 5F&G). Instead, we first treated macrophages with exosomes knocking down CD105, and then added a TGF-β1 inhibitor (SB431542 group) and an inhibitor control solvent (0.1% DMSO) to the treatments. The WB results showed that treatment with exosomes knocking down CD105 resulted in a significant decrease in CD86/IL-6 and an increase in IL-10/ARG-1. After treatment with TGF-β1 inhibitor, the expression level of CD86/IL-6 was elevated and IL-10 /ARG expression was decreased (Fig. 5H&I). In addition, the localization and expression of IL-6 and IL-10 proteins were observed by IF. IF showed that IL-6 and IL-10 were mainly expressed in the cytoplasm. The expression results of IL-6 and IL-10 obtained by IF were consistent with the WB results (Fig. 5B-E). Taken together, TGF-β1 agonist treatment reversed exosomal CD105-induced inhibition of macrophage M1 polarization and TGF-β1 pathway. These results confirmed that exosomal CD105 promotes macrophage M1 polarization by inhibiting TGF-β1/Smad3 pathway activation. Fig. 5Exosome CD105 targets the TGF-β1/Smad3 signaling axis to promote M1 macrophage polarization. A IF Detection of localization, expression and co-localization relationship of CD105 and pSmad3 proteins in each group. Scale bar = 20 μm. B-E IF Detection of localization, expression and relative fluorescence mean optical density of IL-6 and IL-10 proteins in each group. Scale bar = 100 μm. F-I Western blot to detect the expression of CD105, CD86, TGF-β1, Smad3, pSmad3, ARG-1, IL-6, IL-10 in each group. *P < 0.05, **P < 0.01, ***P < 0.001 Exosome CD105 targets the TGF-β1/Smad3 signaling axis to promote M1 macrophage polarization. A IF Detection of localization, expression and co-localization relationship of CD105 and pSmad3 proteins in each group. Scale bar = 20 μm. B-E IF Detection of localization, expression and relative fluorescence mean optical density of IL-6 and IL-10 proteins in each group. Scale bar = 100 μm. F-I Western blot to detect the expression of CD105, CD86, TGF-β1, Smad3, pSmad3, ARG-1, IL-6, IL-10 in each group. *P < 0.05, **P < 0.01, ***P < 0.001 In Vivo Experiments Confirm the Role of Exosomal CD105 in SLE We further evaluated the effect of exosomal CD105 on disease progression in vivo. Exosomal mouse tail vein injections with overexpressed CD105 (oeCD105-exo), overexpressed negative control (oeNC-exo) and knockdown CD105 (shCD105-exo), and negative controls (shNC-exo) (60ug/100ul/each) were injected twice a week for 4 weeks into 12-week-old MRL/lpr mice and PBS was used as a control. At 16 weeks, kidney tissues were collected from all the mice. To investigate the correlation between CD105 and disease, we evaluated kidney tissue samples histologically. Our results showed that the kidney histopathology of MRL/lpr mice injected with oeCD105-exo had significantly deteriorated compared with PBS and oeNC-exo, showing glomerular cellular large crescent formation, extensive vacuolation and granular degeneration of the proximal tubules, and proteinaceous tubular, erythrocytic tubular, and granular tubular patterns were seen in the distal tubules. In contrast, the kidney histopathology of mice injected with shCD105-exo was significantly improved compared with the PBS and shNC-exo groups. This was evidenced by the relatively normal morphology of the glomeruli and the absence of significant lesions in the renal tubules (Fig. 6A). We further evaluated the effects of different treatments on renal pathological changes and function through Masson’s trichrome staining, PAS staining, and serum creatinine (SCr) measurement. Masson’s trichrome staining revealed significantly increased collagen deposition in the oeCD105-exo group, indicating worsening renal interstitial fibrosis, whereas collagen deposition decreased in the shCD105-exo group, suggesting reduced fibrosis severity (Fig. 6D). PAS staining revealed more severe tubular injury in the oeCD105-exo group, manifested as cellular vacuolation and granular degeneration, whereas tubular degeneration improved in the shCD105-exo group with relatively normal glomerular morphology (Fig. 6E). Serum creatinine measurements correlated with staining results: SCr levels were significantly elevated in the oeCD105-exo group, reflecting worsened renal function, while the shCD105-exo group exhibited markedly decreased SCr, indicating improved renal function (Fig. 6H, K). Fig. 6In vivo experiments confirm the role of exosomal CD105 in SLE. A H&E-stained kidney sections of CD105 overexpression/knockdown and corresponding controls. Scale bar = 20 μm. B IF staining with anti-pSmad3 and anti-CD86 in kidney tissues of MRL/lpr mice injected with CD105 overexpressing exosomes. Scale bar = 50 μm. C Fluorescence co-localization analysis of pSmad3 and CD86 in mouse kidney tissue. D Masson-stained renal tissue sections of CD105 overexpression/knockdown and their respective control groups. Upper panels: ×400 magnification, scale bar = 50 μm. Lower panels: ×200 magnification, scale bar = 100 μm. E PAS-stained renal tissue sections of CD105 overexpression/knockdown and their respective control groups. Upper panels: ×400 magnification, scale bar = 50 μm. Lower panels: ×200 magnification, scale bar = 100 μm. F-G Western blot analysis of CD105, CD86, TGF-β1, Smad3, pSmad3, ARG-1, IL-6, and IL-10 expression in mouse kidney tissues after intervention with exosomes overexpressing CD105. I-J Western blot analysis of CD105, CD86, TGF-β1, Smad3, pSmad3, ARG-1, IL-6, and IL-10 expression in mouse kidney tissues following the intervention with exosomes that knock down CD105. H&K The levels of serum creatinine (Scr) in mice across all groups.* P < 0.05, ** P < 0.01, *** P < 0.001. ns, not significant In vivo experiments confirm the role of exosomal CD105 in SLE. A H&E-stained kidney sections of CD105 overexpression/knockdown and corresponding controls. Scale bar = 20 μm. B IF staining with anti-pSmad3 and anti-CD86 in kidney tissues of MRL/lpr mice injected with CD105 overexpressing exosomes. Scale bar = 50 μm. C Fluorescence co-localization analysis of pSmad3 and CD86 in mouse kidney tissue. D Masson-stained renal tissue sections of CD105 overexpression/knockdown and their respective control groups. Upper panels: ×400 magnification, scale bar = 50 μm. Lower panels: ×200 magnification, scale bar = 100 μm. E PAS-stained renal tissue sections of CD105 overexpression/knockdown and their respective control groups. Upper panels: ×400 magnification, scale bar = 50 μm. Lower panels: ×200 magnification, scale bar = 100 μm. F-G Western blot analysis of CD105, CD86, TGF-β1, Smad3, pSmad3, ARG-1, IL-6, and IL-10 expression in mouse kidney tissues after intervention with exosomes overexpressing CD105. I-J Western blot analysis of CD105, CD86, TGF-β1, Smad3, pSmad3, ARG-1, IL-6, and IL-10 expression in mouse kidney tissues following the intervention with exosomes that knock down CD105. H&K The levels of serum creatinine (Scr) in mice across all groups.* P < 0.05, ** P < 0.01, *** P < 0.001. ns, not significant To further validate the effect of CD105-derived exosomes on macrophage activation, we showed by renal tissue WB results that M1 macrophage markers (CD86, IL-6) were significantly increased in the oeCD105-exo injected group compared to PBS and oeNC-exo. Meanwhile, M2 inflammatory factors (ARG-1, IL-10) were decreased, and pathway proteins TGF- β1, and p-Smad3 decreased, and there was no significant difference in Smad3 levels (Fig. 6F, G).Conversely, CD86 and IL-6 decreased significantly in the shCD105-exo injection group, while ARG-1 and IL-10 increased, and the pathway proteins TGF-β1 and pSmad3 were elevated, with no significant difference in Smad3 levels (Fig. 6I, J). We further analyzed the protein expression of pSmad3 and CD86 in kidney tissues of MRL/lpr mice injected with oeCD105-exo by IF. The results suggested that there was a fluorescence co-localization relationship between pSmad3 and CD86 in kidney tissues (Fig. 6B, C). These results suggest that overexpression of CD105 exosomes promoted inflammatory responses in SLE kidneys in vivo, whereas knockdown of CD105 exosomes ameliorated renal inflammation in SLE. Discussion Despite continuous medical advances, the pathogenesis of LN remains complex, and most patients with LN eventually develop end-stage renal disease, which imposes a significant burden on their quality of life and economic status. Therefore, it is particularly important to conduct in-depth studies on the pathogenesis of LN to find effective therapeutic options and biomarkers. In this study, we focused on the role of urine-derived exosomal CD105 in the development of LN, and explored its potential mechanisms in exacerbating LN by inhibiting the TGF-β1/Smad3 pathway-mediated macrophage M1 polarization through a series of experiments. This provides a new perspective for the study of the pathogenesis of LN and potential targets for the development of future therapeutic strategies. Exosomes are nanosized vesicles secreted by cells, that can carry a variety of biologically active molecules such as proteins, lipids, nucleic acids, etc. They also regulate the biological functions of recipient cells, and play an important role in intercellular communication [22, 23]. With the development of high-throughput sequencing technologies, more and more exosome studies have been demonstrated to be involved in the development of human diseases. Previous studies have shown that tumor-derived exosomes play a crucial role in the microenvironment that promotes angiogenesis and metastasis, thereby facilitating tumor growth [24]. Exosomes also have important regulatory roles in autoimmune diseases. Wu et al. found that exosomes promote activation of synoviocytes and amplification of inflammatory responses by delivering inflammatory factors in rheumatoid arthritis [25]. In SLE and its associated complication LN, exosomes have also been found to be involved in the activation of immune cells, inflammatory responses, and tissue damage. Urine exosomes originate from renal cells, and the bioactive molecules they carry can directly reflect the local pathophysiological state of the kidneys, holding significant value for the diagnosis and research of kidney diseases. As stated by Vlassov AV et al., the contents of exosomes reflect the characteristics of the secreting cells, and urine exosomes can reveal pathological changes in renal cells [26]. Xu et al. found that plasma exosome miR-122-5p aggravated LN by inducing macrophage M1 polarization [10]. In our previous study, we analyzed the proteins differentially expressed in urinary exosomes of newly diagnosed SLE patients and healthy controls by quantitative proteomics using TMT. The results showed that the differential proteins were negatively correlated with the clinical indicators of complement C3 and C4, while CD105 topped the list of urinary exosomal differential proteins. CD105 has been studied mainly as a co-receptor for members of the transforming growth factor (TGF)-β family. However, increasing evidence suggests its role not only in angiogenesis-related pathologies (e.g., cancer), but also in other immune dysregulation and inflammatory traits [11–13]. In the present study, we also found that the expression of CD105 was significantly up-regulated in renal tissues of patients with LN, while the expression of TGF-β1 and pSmad3 was significantly down-regulated. This finding suggests that CD105 may play a role in the pathologic process of LN by inhibiting the TGF-β1/Smad3 pathway. As an important mediator of intercellular communication, CD105 carried by urogenic exosomes may exacerbate renal inflammation and tissue injury by modulating the local immune microenvironment. The diagnostic and therapeutic potential of exosomes in LN has received much attention in recent years, and their unique ability to transport substances has made them a new target for LN treatment [27]. Macrophages are an important component of the innate immune system and play a key role in tissue homeostasis, inflammation and host defense [28]. Under different microenvironmental conditions, macrophages can be polarized into two types, M1 (pro-inflammatory) and M2 (anti-inflammatory). Moreover, over-activation of M1-type macrophages is thought to be closely associated with inflammatory responses and tissue damage [29]. It is also believed to mediate key cells in autoimmune diseases, including SLE. Imbalance in macrophage polarization is involved in the development and progression of many autoimmune diseases [30, 31], and macrophage metabolic reprogramming and heterogeneity play an integral role in SLE pathogenesis [32]. Long-term persistent chronic inflammation leads to metabolic imbalances in the SLE microenvironment. Elevated M1-type macrophages and decreased M2-type macrophages and Treg cells exacerbate local inflammation and ultimately lead to organ dysfunction in SLE [33, 34]. Genes associated with M1 tend to be upregulated in patients with SLE compared with healthy donors [35]. SLE activity is also associated with macrophage polarization, and active SLE is more inclined to express pro-inflammatory M1 macrophages [36]. Plasma exosomes from patients with SLE can promote M1 macrophage polarization involved in the pathogenesis of SLE [10]. hUC-MSCs can attenuate diffuse alveolar hemorrhage, alveolar injury, and inflammatory responses by inducing M2 polarization in lupus mice [37]. In conclusion, exosomes have a significant impact on disease progression by regulating macrophage activation. In our study, we demonstrated that CD105 was stably present in the renal tissues and urinary exosomes of patients with SLE, and its expression level was significantly increased. Overexpression of CD105 in exosomes promoted macrophage M1 polarization and exacerbated the inflammatory infiltrate in SLE kidney tissue, whereas knockdown of CD105 inhibited this process. This suggests that exosomal CD105 promotes SLE progression by promoting macrophage M1 polarization. We further explored the mechanism by which exosomal CD105 induces macrophage M1 polarization. TGF-β is a multifunctional mediator that regulates macrophage proliferation, differentiation, apoptosis, adhesion, and migration [38, 39], of which TGF-β1 is a key mediator in the development of fibrosis and inflammation. Moreover, TGF-β1 has been observed to be upregulated in pulmonary, hepatic, and renal fibrosis [38, 40, 41]. The Smads family of proteins are downstream signaling molecules of the TGF-β family and play a key role in transducing TGF-β signaling from the cell surface to the nucleus. Relevant studies have shown that macrophages adapt to chronic inflammation through the synergistic SMAD3/STAT3 signaling pathway triggered by TGF-β1, which regulates macrophage function [42]. TGF-β/Smad3 suppresses inflammation by inducing regulatory T cells (Tregs) [43], and the overexpression of CD105 may disrupt this balance. In in vitro experiments, we intervened macrophages by knocking down and overexpressing CD105 exosomes and further explored its effect on the TGF-β1/Smad3 pathway. The results showed that overexpression of CD105 significantly inhibited the activity of the TGF-β1/Smad3 pathway, while knockdown of CD105 restored the activity of this pathway. In addition, we further verified the direct regulatory effect of CD105 on the TGF-β1/Smad3 pathway by intervention experiments with TGF-β1 agonists and inhibitors. Our in vivo experiments using the MRL/lpr lupus mouse model revealed the compartment-specific effects of CD105 on LN pathogenesis. Overexpression of CD105 in exosomes (oeCD105-exo) exacerbated renal injury, as indicated by worsened crescentic glomerular lesions, tubular damage, and increased fibrosis, accompanied by elevated serum creatinine (SCr) levels, reflecting impaired renal function (Fig. 6H). In contrast, knockdown of CD105 (shCD105-exo) reduced SCr levels, indicating improved kidney function (Fig. 6K). Immunofluorescence analysis showed that M1 macrophages (CD86+) were predominantly localized to the interstitial space, with minimal glomerular involvement, demonstrating a spatial dissociation between glomerular injury and interstitial inflammation (Fig. 6B). Mechanistically, oeCD105-exo inhibited the TGF-β1/Smad3 pathway, reducing pSmad3 expression and nuclear translocation, thus disrupting its anti-inflammatory role in suppressing M1 polarization and maintaining tissue homeostasis [40]. This likely shifted the macrophage balance toward the pro-inflammatory M1 phenotype, driving glomerular damage. The preferential interstitial recruitment of M1 macrophages suggests that CD105 may exert differential effects on glomerular vs. interstitial compartments via compartment-specific signaling or exosome distribution. The TGF-β1/Smad3 pathway is crucial for macrophage adaptation to chronic inflammation via SMAD3/STAT3 synergy [41]. In our study, oeCD105-exo-mediated TGF-β1/Smad3 inhibition likely disrupted this adaptation, promoting M1 polarization. This aligns with evidence that TGF-β1/Smad3 normally induces Treg differentiation and anti-inflammatory cytokine production to suppress M1 activation [43], while its inhibition releases this restraint. The interstitial accumulation of M1 macrophages may reflect their higher responsiveness to SMAD3/STAT3-driven signals in fibroblasts and resident interstitial cells compared to glomerular cells. Interstitial fibroblasts and macrophages drive tubulointerstitial inflammation via cytokine release (e.g., TNF-α, IL-1β) [38, 42]. The differential localization of CD86+ macrophages in the interstitium highlights their role in amplifying interstitial inflammation, while glomerular injury stems from direct CD105-mediated damage to resident cells. Although direct evidence for urinary exosome compartmental targeting is limited, our data suggest that CD105 carried by exosomes may differentially regulate glomerular injury and interstitial inflammation through spatially distinct signaling pathways. To our knowledge, this is the first study to show that CD105 is highly enriched in urinary exosomes from patients with SLE. Urinary-derived exosomal CD105 exacerbates LN by promoting M1-type macrophage polarization through inhibition of the TGF-β1/Smad3 pathway. This finding not only deepens our understanding of the molecular mechanisms of LN pathogenesis, but also highlights the importance of CD105 as a potential target for LN therapy. However, it is important to acknowledge that our study has certain limitations, particularly the relatively small sample size and the need for further validation in larger, diverse patient cohorts. Future studies should also aim to expand the sample size and focus on validating the clinical relevance of CD105 in human LN samples and exploring novel therapeutic strategies targeting the CD105-TGF-β1/Smad3 axis, to enhance the importance and potential value of our current findings. Supplementary Information Below is the link to the electronic supplementary material.Supplementary Material 1 (PDF 970 KB)Supplementary Material 2 (DOCX 12.3 KB)Supplementary Material 3 (DOCX 14.5 KB) Supplementary Material 1 (PDF 970 KB) Supplementary Material 2 (DOCX 12.3 KB) Supplementary Material 3 (DOCX 14.5 KB)